A subset of human pancreatic beta cells express functional CD14 receptors: A signaling pathway for beta cell-related glycolipids, sulfatide and β-galactosylceramide

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 8, 2010, Pages 656-667

  Osterbye, Thomas ^a   Funda, David P ^a,b   Fundová, Petra ^a,b   Månsson, Jan Eric ^c   Tlaskalová Hogenová, Helena ^b   Buschard, Karsten ^a  

^a Rigshospitalet   (Denmark)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CD14; Diabetes; Glycolipids; Human beta cell; Innate immunity

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BETA GALACTOSYLCERAMIDE; CD14 RECEPTOR; GALACTOSYLCERAMIDE; GLUCOSE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD14; SULFATIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STIMULATION; CELL SUBPOPULATION; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; INSULIN RELEASE; MALE; MOLECULAR INTERACTION; MONOCYTE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ADULT; ANIMALS; ANTIGENS, CD14; CELLS, CULTURED; FEMALE; GALACTOSYLCERAMIDES; GLYCOLIPIDS; HUMANS; INSULIN-SECRETING CELLS; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MALE; RATS; SIGNAL TRANSDUCTION; SULFOGLYCOSPHINGOLIPIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78049480162     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1134     Document Type: Article

References (53)

1. Burkart V, Kolb H. Macrophages in islet destruction in autoimmune diabetes mellitus. Immunobiology 1996; 195: 601-613.
2. Walker R, Bone AJ, Cooke A, Baird JD. Distinct macrophage subpopulations in pancreas of prediabetic BB/E rats. Possible role for macrophages in pathogenesis of IDDM. Diabetes 1988; 37: 1301-1304.
3. Bendtzen K, Mandrup-Poulsen T, Nerup J, et al. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986; 232: 1545-1547.
4. Pankewycz OG, Guan JX, Benedict JF. Cytokines as mediators of autoimmune diabetes and diabetic complications. Endocr Rev 1995; 16: 164-176.
5. Onkamo P, Vaananen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of type I diabetes-the analysis of the data on published incidence trends. Diabetologia 1999; 42: 1395-1403.
6. Gale EA. A missing link in the hygiene hypothesis?. Diabetologia 2002; 45: 588-594.
7. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
8. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-1433.
9. Bazil V, Baudys M, Hilgert I, et al. Structural relationship between the soluble and membrane-bound forms of human monocyte surface glycoprotein CD14. Mol Immunol 1989; 26: 657-662.
10. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-680.
11. Funda DP, Tuckova L, Farre MA, et al. CD14 is expressed and released as soluble CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells revisited. Infect Immun 2001; 69: 3772-3781.
12. Jersmann HP, Hii CS, Hodge GL, Ferrante A. Synthesis and surface expression of CD14 by human endothelial cells. Infect Immun 2001; 69: 479-485.
13. Harris CL, Vigar MA, Rey Nores JE, et al. The lipopolysaccharide co-receptor CD14 is present and functional in seminal plasma and expressed on spermatozoa. Immunology 2001; 104: 317-323.
14. Schmitz G, Orso E. CD14 signalling in lipid rafts: new ligands and co-receptors. Curr Opin Lipidol 2002; 13: 513-521.
15. Dentener MA, Bazil V, Von Asmuth EJ, Ceska M, Buurman WA. Involvement of CD14 in lipopolysaccharide-induced tumor necrosis factor-alpha, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J Immunol 1993; 150: 2885-2891.
16. Schumann RR, Rietschel ET, Loppnow H. The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin. Med Microbiol Immunol 1994; 183: 279-297.
17. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
18. Campbell IL, Cutri A, Wilson A, Harrison LC. Evidence for IL-6 production by and effects on the pancreatic beta-cell. J Immunol 1989; 143: 1188-1191.
19. Movahedi B, Van de Casteele M, Caluwe N, et al. Human pancreatic duct cells can produce tumour necrosis factor-alpha that damages neighbouring beta cells and activates dendritic cells. Diabetologia 2004; 47: 998-1008.
20. Vives-Pi M, Somoza N, Fernandez-Alvarez J, et al. Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells. Clin Exp Immunol 2003; 133: 208-218.
21. Alm P, Ekstrom P, Henningsson R, Lundquist I. Morphological evidence for the existence of nitric oxide and carbon monoxide pathways in the rat islets of Langerhans: an immunocytochemical and confocal microscopical study. Diabetologia 1999; 42: 978-986.
22. Roeske-Nielsen A, Fredman P, Mansson JE, Bendtzen K, Buschard K. Beta-galactosylceramide increases and sulfatide decreases cytokine and chemokine production in whole blood cells. Immunol Lett 2004; 91: 205-211.
23. Buschard K, Hoy M, Bokvist K, et al. Sulfatide controls insulin secretion by modulation of ATP-sensitive K(+)-channel activity and Ca(2 + )-dependent exocytosis in rat pancreatic beta-cells. Diabetes 2002; 51: 2514-2521.
24. Fredman P, Mansson JE, Rynmark BM, et al. The glycosphingolipid sulfatide in the islets of Langerhans in rat pancreas is processed through recycling: possible involvement in insulin trafficking. Glycobiology 2000; 10: 39-50.
25. Osterbye T, Jorgensen KH, Fredman P, et al. Sulfatide promotes the folding of proinsulin, preserves insulin crystals, and mediates its monomerization. Glycobiology 2001; 11: 473-479.
26. Buschard K, Schloot NC, Kaas A, et al. Inhibition of insulin-specific autoreactive T-cells by sulfatide which is variably expressed in beta cells. Diabetologia 1999; 42: 1212-1218.
27. Brandhorst H, Brandhorst D, Brendel MD, Hering BJ, Bretzel RG. Assessment of intracellular insulin content during all steps of human islet isolation procedure. Cell Transplant 1998; 7: 489-495.
28. Lacy PE, Davie JM, Finke EH. Prolongation of islet allograft survival following in vitro culture (24 degrees C) and a single injection of ALS. Science 1979; 204: 312-313.
29. Josefsen K, Stenvang JP, Kindmark H, et al. Fluorescence-activated cell sorted rat islet cells and studies of the insulin secretory process. J Endocrinol 1996; 149: 145-154.
30. Ikejima K, Enomoto N, Seabra V, et al. Pronase destroys the lipopolysaccharide receptor CD14 on Kupffer cells. Am J Physiol 1999; 276: G591-G598.
31. Rosengren B, Fredman P, Mansson JE, Svennerholm L. Lysosulfatide (galactosylsphingosine-3-O-sulfate) from metachromatic leukodystrophy and normal human brain. J Neurochem 1989; 52: 1035-1041.
32. Miyazaki J, Araki K, Yamato E, et al. Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 1990; 127: 126-132.
33. Markmann JF, Tomaszewski J, Posselt AM, et al. The effect of islet cell culture in vitro at 24 degrees C on graft survival and MHC antigen expression. Transplantation 1990; 49: 272-277.
34. Bovin LF, Fredman P, Mansson JE, Buschard K, Bendtzen K. In vitro production of cytokines is influenced by sulfatide and its precursor galactosylceramide. FEBS Lett. 1999; 455: 339-343.
35. Ziegler-Heitbrock HW, Thiel E, Futterer A, et al. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 1988; 41: 456-461.
36. Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000; 6: 435-442.
37. Joseph CK, Wright SD, Bornmann WG, et al. Bacterial lipopolysaccharide has structural similarity to ceramide and stimulates ceramide-activated protein kinase in myeloid cells. J Biol Chem 1994; 269: 17606-17610.
38. Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol 2000; 164: 13-17.
39. Pfeiffer A, Bottcher A, Orso E, et al. Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. Eur J Immunol 2001; 31: 3153-3164.
40. Matzinger P. Friendly and dangerous signals: is the tissue in control?. Nat Immunol 2007; 8: 11-13.
41. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin-8 gene expression. J Leukoc Biol 2002; 72: 847-855.
42. Harada Y, Sato C, Kitajima K. Complex formation of 70-kDa heat shock protein with acidic glycolipids and phospholipids. Biochem Biophys Res Commun 2007; 353: 655-660.
43. Campbell IL, Iscaro A, Harrison LC. IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of Langerhans. J Immunol 1988; 141: 2325-2329.
44. Mandrup-Poulsen T, Egeberg J, Nerup J, et al. Ultrastructural studies of time-course and cellular specificity of interleukin-1 mediated islet cytotoxicity. Acta Pathol Microbiol Immunol Scand C 1987; 95: 55-63.
45. Buschard K, Fredman P, Bog-Hansen E, et al. Low serum concentration of sulfatide and presence of sulfated lactosylceramide are associated with type 2 diabetes. The Skaraborg Project. Diabet Med 2005; 22: 1190-1198.
46. Reyna SM, Ghosh S, Tantiwong P, et al. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 2008; 57: 2595-2602.
47. Maedler K, Schumann DM, Sauter N, et al. Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets. Diabetes 2006; 55: 2713-2722.
48. Sai P, Rivereau AS. Prevention of diabetes in the nonobese diabetic mouse by oral immunological treatments. Comparative efficiency of human insulin and two bacterial antigens, lipopolysaccharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae. Diabetes Metab 1996; 22: 341-348.
49. Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal I. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008; 57: 3090-3098.
50. Wen L, Peng J, Li Z, Wong FS. The effect of innate immunity on autoimmune diabetes and the expression of toll-like receptors on pancreatic islets. J Immunol 2004; 172: 3173-3180.
51. Bock T, Kjaer TW, Jorgensen M, et al. Reduction of diabetes incidence in NOD mice by neonatal glucose treatment. APMIS 1991; 99: 989-992.
52. Buschard K, Jorgensen M, Aaen K, Bock T, Josefsen K. Prevention of diabetes mellitus in BB rats by neonatal stimulation of beta cells. Lancet 1990; 335: 134-135.
53. Gotfredsen CF, Buschard K, Frandsen EK. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 1985; 28: 933-935.